SEARCH

SEARCH BY CITATION

References

  • Adolfsson R., Gottfries C. G., Roos B. E. and Winblad B. J. (1979) Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J. Neural Transm. 45, 81105.
  • Ba M., Kong M., Yang H., Ma G., Lu G., Chen S. and Liu Z. (2006) Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesined and L-dopa-treated rats. Neurochem. Res. 31, 13371347.
  • Barria A., Muller D., Derkach V., Griffith L. C. and Sodring T. R. (1997) Regulatory phosphorylation of AMPA-type glutamate receptor by CaM-KII during long-term potentiation. Science 276, 20422045.
  • Bliss T. V. and Collingridge G. L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 3139 (review).
  • Collingridge G. L., Isaac J. T. and Wang Y. T. (2004) Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 5, 952962 (review).
  • Cummings J. L. (1992) Depression and Parkinson’s disease: a review. Am. J. Psychiatry 149, 443454.
  • Da Cunha C., Gevaerd M. S., Vital M. A., Miyoshi E., Andreatini R., Silveira R., Takahashi R. N. and Canteras N. S. (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson’s disease amnesia. Behav. Brain Res. 124, 918.
  • Danysz W., Zajaczkowski W. and Parsons C. G. (1995) Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6, 455474.
  • Derkach V., Barria A. and Soderling T. (1999) Ca2 + /calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl Acad. Sci. USA 96, 32693274.
  • Fernagut P. O., Diguet E., Labattu B. and Tison F. (2002) A simple method to measure stride length as an index of nigro-striatal dysfunction in mice. J. Neurosci. Methods 113, 123130.
  • Ferro M. M., Angelucci M. E., Anselmo-Franci J. A., Canteras N. S. and Da Cunha C. (2007) Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson’s disease. Braz. J. Med. Biol. Res. 40, 8996.
  • Frankland P. W., O’Brien C., Ohno M., Kirkwood A. and Silva A. J. (2001) α-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature 411, 309313.
  • Fukunaga K., Goto S. and Miyamoto E. (1988) Immunohistochemical localization of Ca2 + /calmodulin-dependent protein kinase II in rat brain and various tissues. J. Neurochem. 51, 10701078.
  • Fukunaga K., Sodering T. R. and Miyamoto E. (1992) Activation of Ca2 + /calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J. Biol. Chem. 267, 2252722533.
  • Fukunaga K., Stoppini L., Miyamoto E. and Muller D. (1993) Long-term potentiation is associated with a increased activity of Ca2+ /calmodulin-dependent protein kinase II. J. Biol. Chem. 268, 78637867.
  • Gasbarri A., Verney C., Innocenzi R., Campana E. and Pacitti C. (1994) Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immnohistochemical study. Brain Res. 668, 7179.
  • Gevaerd M. S., Miyoshi E., Silveira R., Canteras N. S., Takahashi R. N. and Da Cunha C. (2001) L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int. J. Neuropsychopharmacol. 4, 361370.
  • Giese K. P., Fedorov N. B., Filipkowski R. K. and Silva A. J. (1998) Autophosphorylation at Thr286 of the alpha calcium/calmodulin kinase II in LTP and learning. Science 279, 870873.
  • Hanson J. E., Orr A. L. and Madison D. V. (2010) Altered hippocampal synaptic physiology in aged parkin-deficient mice. Neuromol. Med. 12, 270276.
  • Harris E. W., Ganong A. H. and Cotman C. W. (1984) Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res. 323, 132137.
  • Heikkila R. E. and Sonsalla P. K. (1987) The use of the MPTP-treated mouse as an animal model of parkinsonism. Can. J. Neurol. Sci. 14, 436440.
  • Heikkila R. E., Manzino L., Cabatt F. S. and Duvoisin R. S. (1984a) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467469.
  • Heikkila R. E., Hess A. and Duvoisin R. C. (1984b) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224, 14511453.
  • Hong Z., Wang G., Gu J., Pan J., Bai L., Zhang S. and Chen S. D. (2007) Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. Eur. J. Neurosci. 26, 15001508.
  • Hornykiewicz O. (1963) The tropical localization and content of noradrenalin and dopamine (3-hydroxytryramine) in the substantia nigra of normal persons and patients with Parkinson’s disease. Wien. Klin. Wochenschr. 75, 309312.
  • Hornykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson’s disease. Adv. Neurol. 45, 1934.
  • Hudman A. and Schulman H. (2002) Neuronal Ca2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Ann. Rev. Biochem. 71, 473510 (review).
  • Jackson-Lewis V., Jackowec M., Burke R. E. and Przedborski S. (1995) Time-course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257269.
  • Jellinger K. (1987) Overview of morphological changes in Parkinson’s disease. Ann. Neurol. 45, 118.
  • Kish S. J., Shannak K. and Hornykicwicz O. (1988) Uncvcn pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysilogic and clinical implications. N. Engl. J. Med. 318, 876880.
  • Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscheeter A., Platania P., Wu B., Pothos E. N. and Shen J. (2009) Impaired dopamine relase and synaptic plasticity in the striatum of Parkin-/- mice. J. Neurochem. 110, 613621.
  • Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680685.
  • Lisman J., Schulman H. and Cline H. (2002) The molecular basis of CaMKII function in synaptic and behavioral memory. Nat. Rev. Neurosci. 3, 175190.
  • Liu S. M., Fa M., Ninan I., Trinchese F., Dauer W. and Arancio O. (2007) Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. Eur. J. Neurosci. 25, 35833596.
  • Lledo P. M., Hjelmstad G. O., Mukhherji S., Sodering T. R., Malenka R. C. and Nicoll R. A. (1995) Calcium/calmodulin-dependent kinase II and long-term potentiation enhance synaptic transmission by the same mechanism. Proc. Natl Acad. Sci. USA 92, 1117511179.
  • Malenka R. C. (1994) Synaptic plasticity in the hippocampus: LTP and LTD. Cell 78, 535538 (review).
  • McGlade-McCulloh E., Yamamoto H., Tan S. E., Brickey D. A. and Sodering T. R. (1993) Phosphorylation and regulation of glutamate receptors by calcium/calmodulin-dependent protein kinase II. Nature 362, 640642.
  • Miyoshi E., Wietzikoski S., Camplessei M., Silveira R., Takahasi R. N. and Da Cunha C. (2002) Imapired learning in a apatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res. Bull. 58, 4147.
  • Moriguchi S., Shioda N., Han F., Narahashi T. and Fukunaga K. (2008) CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region. J. Neurochem. 106, 10921103.
  • Mulkey R. M. and Malenka R. C. (1992) Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron 9, 967975.
  • Nicotra A. and Parvez S. H. (2000) Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153, 157166.
  • Ogawa N., Hirose Y., Ohara S., Ono T. and Watabe Y. (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50, 435441.
  • O’Reilly R. C. and McClelland J. L. (1994) Hippocampal conjunctive encoding, strage, and recall: avoiding a trade-off. Hippocampus 4, 661682.
  • Perry J. C., Da Cunha C., Anselmo-Franci J., Andreatini R., Miyoshi E., Tufik S. and Vital M. A. (2004) Behavioral and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur. J. Pharmacol. 484, 225233.
  • Pillon B., Dubois B., Cusimano G., Bonnet A. M., Lhermitte F. and Agid Y. (1989) Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J. Neurol. Neurosurg. Psychiatry 52, 201206.
  • Poncer J. C., Esteban J. A. and Malinow R. (2002) Multiple mechanism for the potentiation of AMPA receptor-mediated transmission by alpha- Ca2 + /calmodulin-dependent protein kinase II. J. Neurosci. 22, 44064411.
  • Prickaerts J., Van Staveren W. C. G., Sik A., Markerink-Van Ittersum M., Niewohner U., Van der Staay F. J., Blokland A. and De Vente J. (2002) Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113, 349359.
  • Quinn L. P., Perren M. J., Brackenborough K. T., Woodhams P. L., Vidgeon-Hart M., Chapman H., Pangalos M. N., Upton N. and Virley D. J. (2007) A beam walking apparatus to assess behavioral impairments in MPTP-treaed mice: Pharmacological validation with R-(-)-deprenyl. J. Neurosci. Res. 164, 4349.
  • Reksidler A. B., Lima M. M., Zanata S. M., Machado H. B., Da Cunha C., Andreatini R., Tufik S. and Vital M. A. (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur. J. Pharmacol. 560, 163175.
  • Reksidler A. B., Lima M. M., Dombrowski P., Andersen M. L., Zanata S. M., Andreatini R., Tufik S. and Vital M. A. (2008) Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson’s disease. J. Neurosci. Methods 167, 268277.
  • Ricaurte G. A., Irwin I., Forno L. S., Delanny L. E., Langston E. and Langston J. W. (1987) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403, 4351.
  • Rozas G., Lopez-Martin E., Guerra M. J. and Labandeira-Garcia J. L. (1998) The overall rod performance test in the MPTP-trated mouse model of Parkinsonism. J. Neurosci. Methods 83, 165175.
  • Schneider J. S., Tinker I. P., Van Velson M. and Giardiniere M. (2000) Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res. 860, 190194.
  • Shi S. H., Hayashi Y., Petralia R. S., Zaman S. H., Wenthold R. J., Svoboda K. and Malinow R. (1999) Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 284, 18111826.
  • Smeyne R. J. and Jackson-Lewis V. (2005) The MPTP model of Parkinson’s disease. Brain Res. Mol. Brain Res. 134, 5766.
  • Song I. and Huganir R. L. (2002) Regulation of AMPA receptor during synaptic plasticity. Trends Neurosci. 25, 578588 (review).
  • Sonsalla P. K. and Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339345.
  • Tanila H., Bjorklund M. and Riekkinen P., Jr (1998) Cognitive changes in mice following moderate MPTP exposure. Brain Res. Bull. 45, 577582.
  • Tingley W. G., Rocke K. W., Thompson A. K. and Huganir R. L. (1993) Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364, 7073.
  • Walsh K. and Bennett G. (2001) Parkinson’s disease and anxiety. Postgrad. Med. J. 77, 8993.
  • Wang J. H. and Kelly P. T. (1995) Postsynaptic injection of Ca2 + /CaM induces synaptic potentiation requiring CaMKII and PKC activity. Neuron 15, 443452.
  • Wang Y., Chandran J. S., Cai H. B. and Mattson M. P. (2008) DJ-1 is essential for long-term depression at hippocampal CA1 synapses. Neuromol. Med. 10, 4045.
  • Williams S., Mmbaga N. and Chirwa S. (2006) Dopaminergic D1 receptor agonist SKF38393 induces GAP-43 expression and long-term potentiation in hippocampus in vivo. Neurosci. Lett. 402, 4650.
  • Xia Z. and Storm D. R. (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat. Rev. Neurosci. 6, 267276.
  • Yamagata Y. (2003) New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J. Pharmacol. Sci. 93, 2229.
  • Zhu G., Chen Y., Huang Y. Y., Li Q. L. and Behnisch T. (2011) MPTP-mediated hippocampal dopamine deprivation modulates synaptic transmission and active-dependent synaptic plasticity. Toxicol. Appl. Pharmacol. 254, 332341.